Savara Inc. Stock
Price
Target price
€4.08
€4.08
6.810%
0.26
6.810%
€5.00
02.07.24 / Frankfurt
WKN: A2DQ2B / Symbol: MSTX / Name: Savara / Stock / Pharmaceuticals / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Savara Inc. Stock
Savara Inc. dominated the market today, gaining €0.26 (6.810%).
Currently there is a rather positive sentiment for Savara Inc. with 4 Buy predictions and 2 Sell predictions.
With a target price of 5 € there is a positive potential of 22.55% for Savara Inc. compared to the current price of 4.08 €.
Our community identified positive and negative aspects for Savara Inc. stock for the coming years. 1 users see the criterium "Expected Cash Flow" as a plus for the Savara Inc. stock. On the other hand our users think that "Business model" could be a problem in the future.
Pros and Cons of Savara Inc. in the next few years
Pros
?
B****
?
M***** P*******
?
C******** o* t** e**********
Cons
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Savara Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Savara Inc. | 6.810% | 8.523% | -0.521% | 31.724% | -11.574% | 182.963% | 60.876% |
| Avid Bioservices Inc | - | -1.493% | -9.589% | -46.341% | 8.197% | -70.270% | 23.688% |
| Rockwell Medical Inc. | -1.540% | -8.466% | -2.444% | -63.322% | -10.208% | -79.866% | -94.487% |
| Gritstone Oncology Inc | 1.650% | -20.444% | -21.777% | -69.865% | -71.098% | -92.985% | - |
News
Savara Announces Pricing of $100.0 Million Underwritten Offering of Common Stock
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the pricing of an underwritten offering of 26,246,720 shares of its
Savara Announces Molgramostim Nebulizer Solution (Molgramostim) Achieved Statistical Significance for Primary Endpoint and Multiple Secondary Endpoints in IMPALA-2, a Pivotal Phase 3 Clinical Trial in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced positive results from the pivotal, Phase 3 IMPALA-2
Savara to Host Investor Call to Discuss Top Line Results From Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that it will host a conference call and webcast tomorrow